Phase III Study Shows Genentech’s Actemra® (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA)
Genentech’s Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer
Chugai Announces License Agreement for Recycling Antibody SA237
This ETF holds a swath of large- and mid-cap U.S. healthcare companies.
Maxygen MAXY announced that its partner Roche RHHBY placed a hold on development of Maxy-Alpha--the first of Maxygen's shuffled proteins to enter clinical development--and we're lowering our fair value estimate accordingly. While we had only placed a 20% probability on the eventual approval of ...
Ariel International marks the firm’s first foray into foreign-stock investing. It has been a performance success so far.
Firm has a promising strategy of combining expertise in both areas to generate a growing personalized medicine pipeline.
First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.
Top managers continue to focus on higher-quality dividend-paying stocks in a fully valued market.
Readers say diversification and exposure to good companies call for looking beyond the U.S.